[1]
Creasman WT, Odicino F, Maisonneuve P, Quinn MA, Beller U, Benedet JL, Heintz A, Ngan H, Pecorelli S. Carcinoma of the Corpus Uteri. International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics. 2006 Nov:95 Suppl 1():S105-S143. doi: 10.1016/S0020-7292(06)60031-3. Epub
[PubMed PMID: 29644661]
[2]
Brinton LA, Felix AS, McMeekin DS, Creasman WT, Sherman ME, Mutch D, Cohn DE, Walker JL, Moore RG, Downs LS, Soslow RA, Zaino R. Etiologic heterogeneity in endometrial cancer: evidence from a Gynecologic Oncology Group trial. Gynecologic oncology. 2013 May:129(2):277-84. doi: 10.1016/j.ygyno.2013.02.023. Epub 2013 Feb 26
[PubMed PMID: 23485770]
[3]
Conlon N, Leitao MM Jr, Abu-Rustum NR, Soslow RA. Grading uterine endometrioid carcinoma: a proposal that binary is best. The American journal of surgical pathology. 2014 Dec:38(12):1583-7. doi: 10.1097/PAS.0000000000000327. Epub
[PubMed PMID: 25229772]
[4]
Altman AD, Ferguson SE, Atenafu EG, Köbel M, McAlpine JN, Panzarella T, Lau S, Gien LT, Gilks B, Clarke B, Cameron A, Nelson G, Han G, Samouëlian V, Ho TC, Louie K, Bernardini MQ. Canadian high risk endometrial cancer (CHREC) consortium: analyzing the clinical behavior of high risk endometrial cancers. Gynecologic oncology. 2015 Nov:139(2):268-74. doi: 10.1016/j.ygyno.2015.09.001. Epub 2015 Sep 6
[PubMed PMID: 26352641]
[5]
Casey MJ, Bewtra C, Lynch HT, Snyder CL, Stacey M. Endometrial cancers in mutation carriers from hereditary breast ovarian cancer syndrome kindreds: report from the Creighton University Hereditary Cancer Registry with review of the implications. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2015 May:25(4):650-6. doi: 10.1097/IGC.0000000000000402. Epub
[PubMed PMID: 25756400]
Level 2 (mid-level) evidence
[6]
Lax SF. Pathology of Endometrial Carcinoma. Advances in experimental medicine and biology. 2017:943():75-96
[PubMed PMID: 27910065]
Level 3 (low-level) evidence
[7]
Lax SF, Kurman RJ, Pizer ES, Wu L, Ronnett BM. A binary architectural grading system for uterine endometrial endometrioid carcinoma has superior reproducibility compared with FIGO grading and identifies subsets of advance-stage tumors with favorable and unfavorable prognosis. The American journal of surgical pathology. 2000 Sep:24(9):1201-8
[PubMed PMID: 10976693]
[8]
Hamilton CA, Cheung MK, Osann K, Chen L, Teng NN, Longacre TA, Powell MA, Hendrickson MR, Kapp DS, Chan JK. Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers. British journal of cancer. 2006 Mar 13:94(5):642-6
[PubMed PMID: 16495918]
[9]
Casey MJ, Colanta AB. Müllerian intra-abdominal carcinomatosis in hereditary breast ovarian cancer syndrome: implications for risk-reducing surgery. Familial cancer. 2016 Jul:15(3):371-84. doi: 10.1007/s10689-016-9878-4. Epub
[PubMed PMID: 26875157]
Level 3 (low-level) evidence
[10]
Holcomb K, Delatorre R, Pedemonte B, McLeod C, Anderson L, Chambers J. E-cadherin expression in endometrioid, papillary serous, and clear cell carcinoma of the endometrium. Obstetrics and gynecology. 2002 Dec:100(6):1290-5
[PubMed PMID: 12468176]
[11]
Reid-Nicholson M, Iyengar P, Hummer AJ, Linkov I, Asher M, Soslow RA. Immunophenotypic diversity of endometrial adenocarcinomas: implications for differential diagnosis. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc. 2006 Aug:19(8):1091-100
[PubMed PMID: 16648864]
[12]
Hoang LN, Han G, McConechy M, Lau S, Chow C, Gilks CB, Huntsman DG, Köbel M, Lee CH. Immunohistochemical characterization of prototypical endometrial clear cell carcinoma--diagnostic utility of HNF-1β and oestrogen receptor. Histopathology. 2014 Mar:64(4):585-96. doi: 10.1111/his.12286. Epub 2013 Dec 7
[PubMed PMID: 24103020]
[13]
Hoang LN, McConechy MK, Meng B, McIntyre JB, Ewanowich C, Gilks CB, Huntsman DG, Köbel M, Lee CH. Targeted mutation analysis of endometrial clear cell carcinoma. Histopathology. 2015 Apr:66(5):664-74. doi: 10.1111/his.12581. Epub 2015 Jan 13
[PubMed PMID: 25308272]
[14]
Fadare O, Gwin K, Desouki MM, Crispens MA, Jones HW 3rd, Khabele D, Liang SX, Zheng W, Mohammed K, Hecht JL, Parkash V. The clinicopathologic significance of p53 and BAF-250a (ARID1A) expression in clear cell carcinoma of the endometrium. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc. 2013 Aug:26(8):1101-10. doi: 10.1038/modpathol.2013.35. Epub 2013 Mar 22
[PubMed PMID: 23524907]
[15]
Lim D, Murali R, Murray MP, Veras E, Park KJ, Soslow RA. Morphological and Immunohistochemical Reevaluation of Tumors Initially Diagnosed as Ovarian Endometrioid Carcinoma With Emphasis on High-grade Tumors. The American journal of surgical pathology. 2016 Mar:40(3):302-12. doi: 10.1097/PAS.0000000000000550. Epub
[PubMed PMID: 26551621]
[16]
Howitt BE, Hanamornroongruang S, Lin DI, Conner JE, Schulte S, Horowitz N, Crum CP, Meserve EE. Evidence for a dualistic model of high-grade serous carcinoma: BRCA mutation status, histology, and tubal intraepithelial carcinoma. The American journal of surgical pathology. 2015 Mar:39(3):287-93. doi: 10.1097/PAS.0000000000000369. Epub
[PubMed PMID: 25581732]
[17]
Sherman ME, Devesa SS. Analysis of racial differences in incidence, survival, and mortality for malignant tumors of the uterine corpus. Cancer. 2003 Jul 1:98(1):176-86
[PubMed PMID: 12833470]
[18]
Ueda SM, Kapp DS, Cheung MK, Shin JY, Osann K, Husain A, Teng NN, Berek JS, Chan JK. Trends in demographic and clinical characteristics in women diagnosed with corpus cancer and their potential impact on the increasing number of deaths. American journal of obstetrics and gynecology. 2008 Feb:198(2):218.e1-6. doi: 10.1016/j.ajog.2007.08.075. Epub
[PubMed PMID: 18226630]
[19]
Amant F, Moerman P, Neven P, Timmerman D, Van Limbergen E, Vergote I. Endometrial cancer. Lancet (London, England). 2005 Aug 6-12:366(9484):491-505
[PubMed PMID: 16084259]
[20]
van Meurs HS, Bleeker MC, van der Velden J, Overbeek LI, Kenter GG, Buist MR. The incidence of endometrial hyperplasia and cancer in 1031 patients with a granulosa cell tumor of the ovary: long-term follow-up in a population-based cohort study. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2013 Oct:23(8):1417-22. doi: 10.1097/IGC.0b013e3182a57fb4. Epub
[PubMed PMID: 24257556]
Level 2 (mid-level) evidence
[21]
Ottolina J, Ferrandina G, Gadducci A, Scollo P, Lorusso D, Giorda G, Breda E, Savarese A, Candiani M, Zullo F, Mangili G. Is the endometrial evaluation routinely required in patients with adult granulosa cell tumors of the ovary? Gynecologic oncology. 2015 Feb:136(2):230-4. doi: 10.1016/j.ygyno.2014.12.016. Epub 2014 Dec 17
[PubMed PMID: 25527364]
[22]
Navaratnarajah R, Pillay OC, Hardiman P. Polycystic ovary syndrome and endometrial cancer. Seminars in reproductive medicine. 2008 Jan:26(1):62-71. doi: 10.1055/s-2007-992926. Epub
[PubMed PMID: 18181084]
[23]
Papaioannou S, Tzafettas J. Anovulation with or without PCO, hyperandrogenaemia and hyperinsulinaemia as promoters of endometrial and breast cancer. Best practice & research. Clinical obstetrics & gynaecology. 2010 Feb:24(1):19-27. doi: 10.1016/j.bpobgyn.2008.11.010. Epub 2009 Mar 4
[PubMed PMID: 19264556]
[24]
Beral V, Bull D, Reeves G, Million Women Study Collaborators. Endometrial cancer and hormone-replacement therapy in the Million Women Study. Lancet (London, England). 2005 Apr 30-May 6:365(9470):1543-51
[PubMed PMID: 15866308]
[25]
Yang HP, Cook LS, Weiderpass E, Adami HO, Anderson KE, Cai H, Cerhan JR, Clendenen TV, Felix AS, Friedenreich CM, Garcia-Closas M, Goodman MT, Liang X, Lissowska J, Lu L, Magliocco AM, McCann SE, Moysich KB, Olson SH, Petruzella S, Pike MC, Polidoro S, Ricceri F, Risch HA, Sacerdote C, Setiawan VW, Shu XO, Spurdle AB, Trabert B, Webb PM, Wentzensen N, Xiang YB, Xu Y, Yu H, Zeleniuch-Jacquotte A, Brinton LA. Infertility and incident endometrial cancer risk: a pooled analysis from the epidemiology of endometrial cancer consortium (E2C2). British journal of cancer. 2015 Mar 3:112(5):925-33. doi: 10.1038/bjc.2015.24. Epub 2015 Feb 17
[PubMed PMID: 25688738]
[26]
Kitson SJ, Evans DG, Crosbie EJ. Identifying High-Risk Women for Endometrial Cancer Prevention Strategies: Proposal of an Endometrial Cancer Risk Prediction Model. Cancer prevention research (Philadelphia, Pa.). 2017 Jan:10(1):1-13. doi: 10.1158/1940-6207.CAPR-16-0224. Epub 2016 Dec 13
[PubMed PMID: 27965288]
[27]
Setiawan VW, Yang HP, Pike MC, McCann SE, Yu H, Xiang YB, Wolk A, Wentzensen N, Weiss NS, Webb PM, van den Brandt PA, van de Vijver K, Thompson PJ, Australian National Endometrial Cancer Study Group, Strom BL, Spurdle AB, Soslow RA, Shu XO, Schairer C, Sacerdote C, Rohan TE, Robien K, Risch HA, Ricceri F, Rebbeck TR, Rastogi R, Prescott J, Polidoro S, Park Y, Olson SH, Moysich KB, Miller AB, McCullough ML, Matsuno RK, Magliocco AM, Lurie G, Lu L, Lissowska J, Liang X, Lacey JV Jr, Kolonel LN, Henderson BE, Hankinson SE, Håkansson N, Goodman MT, Gaudet MM, Garcia-Closas M, Friedenreich CM, Freudenheim JL, Doherty J, De Vivo I, Courneya KS, Cook LS, Chen C, Cerhan JR, Cai H, Brinton LA, Bernstein L, Anderson KE, Anton-Culver H, Schouten LJ, Horn-Ross PL. Type I and II endometrial cancers: have they different risk factors? Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2013 Jul 10:31(20):2607-18. doi: 10.1200/JCO.2012.48.2596. Epub 2013 Jun 3
[PubMed PMID: 23733771]
[28]
Lukanova A, Lundin E, Akhmedkhanov A, Micheli A, Rinaldi S, Zeleniuch-Jacquotte A, Lenner P, Muti P, Biessy C, Krogh V, Berrino F, Hallmans G, Riboli E, Kaaks R, Toniolo P. Circulating levels of sex steroid hormones and risk of ovarian cancer. International journal of cancer. 2003 May 1:104(5):636-42
[PubMed PMID: 12594820]
[29]
Bjørge T, Engeland A, Tretli S, Weiderpass E. Body size in relation to cancer of the uterine corpus in 1 million Norwegian women. International journal of cancer. 2007 Jan 15:120(2):378-83
[PubMed PMID: 17066451]
[30]
Gehrig PA, Bae-Jump VL, Boggess JF, Groben PA, Fowler WC Jr, Van Le L. Association between uterine serous carcinoma and breast cancer. Gynecologic oncology. 2004 Jul:94(1):208-11
[PubMed PMID: 15262144]
[31]
Segev Y, Rosen B, Lubinski J, Gronwald J, Lynch HT, Moller P, Kim-Sing C, Ghadirian P, Karlan B, Eng C, Gilchrist D, Neuhausen SL, Eisen A, Friedman E, Euhus D, Ping S, Narod SA, Hereditary Breast Cancer Study Group. Risk factors for endometrial cancer among women with a BRCA1 or BRCA2 mutation: a case control study. Familial cancer. 2015 Sep:14(3):383-91. doi: 10.1007/s10689-015-9798-8. Epub
[PubMed PMID: 25838159]
Level 2 (mid-level) evidence
[32]
Lynch HT, Lanspa S, Shaw T, Casey MJ, Rendell M, Stacey M, Townley T, Snyder C, Hitchins M, Bailey-Wilson J. Phenotypic and genotypic heterogeneity of Lynch syndrome: a complex diagnostic challenge. Familial cancer. 2018 Jul:17(3):403-414. doi: 10.1007/s10689-017-0053-3. Epub
[PubMed PMID: 29071502]
Level 3 (low-level) evidence
[33]
Lancaster JM, Powell CB, Kauff ND, Cass I, Chen LM, Lu KH, Mutch DG, Berchuck A, Karlan BY, Herzog TJ, Society of Gynecologic Oncologists Education Committee. Society of Gynecologic Oncologists Education Committee statement on risk assessment for inherited gynecologic cancer predispositions. Gynecologic oncology. 2007 Nov:107(2):159-62
[PubMed PMID: 17950381]
[34]
Pilarski R, Stephens JA, Noss R, Fisher JL, Prior TW. Predicting PTEN mutations: an evaluation of Cowden syndrome and Bannayan-Riley-Ruvalcaba syndrome clinical features. Journal of medical genetics. 2011 Aug:48(8):505-12. doi: 10.1136/jmg.2011.088807. Epub 2011 Jun 9
[PubMed PMID: 21659347]
[35]
Ring KL, Garcia C, Thomas MH, Modesitt SC. Current and future role of genetic screening in gynecologic malignancies. American journal of obstetrics and gynecology. 2017 Nov:217(5):512-521. doi: 10.1016/j.ajog.2017.04.011. Epub 2017 Apr 12
[PubMed PMID: 28411145]
[36]
Iversen L, Sivasubramaniam S, Lee AJ, Fielding S, Hannaford PC. Lifetime cancer risk and combined oral contraceptives: the Royal College of General Practitioners' Oral Contraception Study. American journal of obstetrics and gynecology. 2017 Jun:216(6):580.e1-580.e9. doi: 10.1016/j.ajog.2017.02.002. Epub 2017 Feb 8
[PubMed PMID: 28188769]
[37]
Setiawan VW, Pike MC, Karageorgi S, Deming SL, Anderson K, Bernstein L, Brinton LA, Cai H, Cerhan JR, Cozen W, Chen C, Doherty J, Freudenheim JL, Goodman MT, Hankinson SE, Lacey JV Jr, Liang X, Lissowska J, Lu L, Lurie G, Mack T, Matsuno RK, McCann S, Moysich KB, Olson SH, Rastogi R, Rebbeck TR, Risch H, Robien K, Schairer C, Shu XO, Spurdle AB, Strom BL, Thompson PJ, Ursin G, Webb PM, Weiss NS, Wentzensen N, Xiang YB, Yang HP, Yu H, Horn-Ross PL, De Vivo I, Australian National Endometrial Cancer Study Group. Age at last birth in relation to risk of endometrial cancer: pooled analysis in the epidemiology of endometrial cancer consortium. American journal of epidemiology. 2012 Aug 15:176(4):269-78
[PubMed PMID: 22831825]
[38]
Hinkula M, Pukkala E, Kyyrönen P, Kauppila A. Grand multiparity and incidence of endometrial cancer: a population-based study in Finland. International journal of cancer. 2002 Apr 20:98(6):912-5
[PubMed PMID: 11948472]
[39]
Jordan SJ, Na R, Johnatty SE, Wise LA, Adami HO, Brinton LA, Chen C, Cook LS, Dal Maso L, De Vivo I, Freudenheim JL, Friedenreich CM, La Vecchia C, McCann SE, Moysich KB, Lu L, Olson SH, Palmer JR, Petruzella S, Pike MC, Rebbeck TR, Ricceri F, Risch HA, Sacerdote C, Setiawan VW, Sponholtz TR, Shu XO, Spurdle AB, Weiderpass E, Wentzensen N, Yang HP, Yu H, Webb PM. Breastfeeding and Endometrial Cancer Risk: An Analysis From the Epidemiology of Endometrial Cancer Consortium. Obstetrics and gynecology. 2017 Jun:129(6):1059-1067. doi: 10.1097/AOG.0000000000002057. Epub
[PubMed PMID: 28486362]
[40]
Lafranconi A, Micek A, Galvano F, Rossetti S, Del Pup L, Berretta M, Facchini G. Coffee Decreases the Risk of Endometrial Cancer: A Dose-Response Meta-Analysis of Prospective Cohort Studies. Nutrients. 2017 Nov 9:9(11):. doi: 10.3390/nu9111223. Epub 2017 Nov 9
[PubMed PMID: 29120352]
Level 1 (high-level) evidence
[41]
Hashibe M, Galeone C, Buys SS, Gren L, Boffetta P, Zhang ZF, La Vecchia C. Coffee, tea, caffeine intake, and the risk of cancer in the PLCO cohort. British journal of cancer. 2015 Sep 1:113(5):809-16. doi: 10.1038/bjc.2015.276. Epub 2015 Aug 20
[PubMed PMID: 26291054]
[42]
Playdon MC, Coburn SB, Moore SC, Brinton LA, Wentzensen N, Anderson G, Wallace R, Falk RT, Pfeiffer R, Xu X, Trabert B. Alcohol and oestrogen metabolites in postmenopausal women in the Women's Health Initiative Observational Study. British journal of cancer. 2018 Feb 6:118(3):448-457. doi: 10.1038/bjc.2017.419. Epub 2017 Dec 12
[PubMed PMID: 29235567]
Level 2 (mid-level) evidence
[43]
Viswanathan AN, Feskanich D, De Vivo I, Hunter DJ, Barbieri RL, Rosner B, Colditz GA, Hankinson SE. Smoking and the risk of endometrial cancer: results from the Nurses' Health Study. International journal of cancer. 2005 May 10:114(6):996-1001
[PubMed PMID: 15645490]
[44]
Pessoa JN, Freitas AC, Guimaraes RA, Lima J, Dos Reis HL, Filho AC. Endometrial Assessment: When is it Necessary? Journal of clinical medicine research. 2014 Feb:6(1):21-5. doi: 10.4021/jocmr1684w. Epub 2013 Dec 13
[PubMed PMID: 24400027]
[45]
Bakkum-Gamez JN, Gonzalez-Bosquet J, Laack NN, Mariani A, Dowdy SC. Current issues in the management of endometrial cancer. Mayo Clinic proceedings. 2008 Jan:83(1):97-112. doi: 10.4065/83.1.97. Epub
[PubMed PMID: 18174012]
[46]
van Hanegem N, Prins MM, Bongers MY, Opmeer BC, Sahota DS, Mol BW, Timmermans A. The accuracy of endometrial sampling in women with postmenopausal bleeding: a systematic review and meta-analysis. European journal of obstetrics, gynecology, and reproductive biology. 2016 Feb:197():147-55. doi: 10.1016/j.ejogrb.2015.12.008. Epub 2015 Dec 19
[PubMed PMID: 26748390]
Level 1 (high-level) evidence
[47]
Trimble CL, Kauderer J, Zaino R, Silverberg S, Lim PC, Burke JJ 2nd, Alberts D, Curtin J. Concurrent endometrial carcinoma in women with a biopsy diagnosis of atypical endometrial hyperplasia: a Gynecologic Oncology Group study. Cancer. 2006 Feb 15:106(4):812-9
[PubMed PMID: 16400639]
[48]
Bel S, Billard C, Godet J, Viviani V, Akladios C, Host A, Faller E, Boisrame T, Hummel M, Baldauf JJ, Lecointre L, Garbin O. Risk of malignancy on suspicion of polyps in menopausal women. European journal of obstetrics, gynecology, and reproductive biology. 2017 Sep:216():138-142. doi: 10.1016/j.ejogrb.2017.07.013. Epub 2017 Jul 15
[PubMed PMID: 28763739]
[49]
Timmermans A, Opmeer BC, Khan KS, Bachmann LM, Epstein E, Clark TJ, Gupta JK, Bakour SH, van den Bosch T, van Doorn HC, Cameron ST, Giusa MG, Dessole S, Dijkhuizen FPHLJ, Ter Riet G, Mol BWJ. Endometrial thickness measurement for detecting endometrial cancer in women with postmenopausal bleeding: a systematic review and meta-analysis. Obstetrics and gynecology. 2010 Jul:116(1):160-167. doi: 10.1097/AOG.0b013e3181e3e7e8. Epub
[PubMed PMID: 20567183]
Level 1 (high-level) evidence
[50]
Wang J, Wieslander C, Hansen G, Cass I, Vasilev S, Holschneider CH. Thin endometrial echo complex on ultrasound does not reliably exclude type 2 endometrial cancers. Gynecologic oncology. 2006 Apr:101(1):120-5
[PubMed PMID: 16307792]
[51]
Pennant ME, Mehta R, Moody P, Hackett G, Prentice A, Sharp SJ, Lakshman R. Premenopausal abnormal uterine bleeding and risk of endometrial cancer. BJOG : an international journal of obstetrics and gynaecology. 2017 Feb:124(3):404-411. doi: 10.1111/1471-0528.14385. Epub 2016 Oct 20
[PubMed PMID: 27766759]
[52]
Sweet MG, Schmidt-Dalton TA, Weiss PM, Madsen KP. Evaluation and management of abnormal uterine bleeding in premenopausal women. American family physician. 2012 Jan 1:85(1):35-43
[PubMed PMID: 22230306]
[53]
ACOG Committee on Practice Bulletins--Gynecology. American College of Obstetricians and Gynecologists.. ACOG practice bulletin: management of anovulatory bleeding. International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics. 2001 Mar:72(3):263-71
[PubMed PMID: 11296797]
[54]
Gitsch G, Hanzal E, Jensen D, Hacker NF. Endometrial cancer in premenopausal women 45 years and younger. Obstetrics and gynecology. 1995 Apr:85(4):504-8
[PubMed PMID: 7898824]
[55]
AlHilli MM, Dowdy SC, Weaver AL, St Sauver JL, Keeney GL, Mariani A, Podratz KC, Bakkum-Gamez JN. Incidence and factors associated with synchronous ovarian and endometrial cancer: a population-based case-control study. Gynecologic oncology. 2012 Apr:125(1):109-13. doi: 10.1016/j.ygyno.2011.12.444. Epub 2011 Dec 28
[PubMed PMID: 22210467]
Level 2 (mid-level) evidence
[56]
Dogan A, Schultheis B, Rezniczek GA, Hilal Z, Cetin C, Häusler G, Tempfer CB. Synchronous Endometrial and Ovarian Cancer in Young Women: Case Report and Review of the Literature. Anticancer research. 2017 Mar:37(3):969-978
[PubMed PMID: 28314254]
Level 3 (low-level) evidence
[57]
Walsh C, Holschneider C, Hoang Y, Tieu K, Karlan B, Cass I. Coexisting ovarian malignancy in young women with endometrial cancer. Obstetrics and gynecology. 2005 Oct:106(4):693-9
[PubMed PMID: 16199623]
[58]
Rossi L, Le Frere-Belda MA, Laurent-Puig P, Buecher B, De Pauw A, Stoppa-Lyonnet D, Canlorbe G, Caron O, Borghese B, Colas C, Delhomelle H, Chabbert-Buffet N, Grandjouan S, Lecuru F, Bats AS. Clinicopathologic Characteristics of Endometrial Cancer in Lynch Syndrome: A French Multicenter Study. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2017 Jun:27(5):953-960. doi: 10.1097/IGC.0000000000000985. Epub
[PubMed PMID: 28525912]
Level 2 (mid-level) evidence
[59]
Lai CR, Hsu CY, Hang JF, Li AF. The Diagnostic Value of Routine Papanicolaou Smears for Detecting Endometrial Cancers: An Update. Acta cytologica. 2015:59(4):315-8. doi: 10.1159/000438975. Epub 2015 Aug 29
[PubMed PMID: 26315394]
[60]
Tzur T, Kessous R, Weintraub AY. Current strategies in the diagnosis of endometrial cancer. Archives of gynecology and obstetrics. 2017 Jul:296(1):5-14. doi: 10.1007/s00404-017-4391-z. Epub 2017 May 15
[PubMed PMID: 28508342]
[61]
Gkrozou F, Dimakopoulos G, Vrekoussis T, Lavasidis L, Koutlas A, Navrozoglou I, Stefos T, Paschopoulos M. Hysteroscopy in women with abnormal uterine bleeding: a meta-analysis on four major endometrial pathologies. Archives of gynecology and obstetrics. 2015 Jun:291(6):1347-54. doi: 10.1007/s00404-014-3585-x. Epub 2014 Dec 19
[PubMed PMID: 25524536]
Level 1 (high-level) evidence
[62]
Chang YN, Zhang Y, Wang YJ, Wang LP, Duan H. Effect of hysteroscopy on the peritoneal dissemination of endometrial cancer cells: a meta-analysis. Fertility and sterility. 2011 Oct:96(4):957-61. doi: 10.1016/j.fertnstert.2011.07.1146. Epub 2011 Aug 26
[PubMed PMID: 21872230]
Level 1 (high-level) evidence
[63]
Chen J, Clark LH, Kong WM, Yan Z, Han C, Zhao H, Liu TT, Zhang TQ, Song D, Jiao SM, Zhou C. Does hysteroscopy worsen prognosis in women with type II endometrial carcinoma? PloS one. 2017:12(3):e0174226. doi: 10.1371/journal.pone.0174226. Epub 2017 Mar 23
[PubMed PMID: 28334032]
[64]
Goldstein RB, Bree RL, Benson CB, Benacerraf BR, Bloss JD, Carlos R, Fleischer AC, Goldstein SR, Hunt RB, Kurman RJ, Kurtz AB, Laing FC, Parsons AK, Smith-Bindman R, Walker J. Evaluation of the woman with postmenopausal bleeding: Society of Radiologists in Ultrasound-Sponsored Consensus Conference statement. Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine. 2001 Oct:20(10):1025-36
[PubMed PMID: 11587008]
Level 3 (low-level) evidence
[65]
Gimpelson RJ, Rappold HO. A comparative study between panoramic hysteroscopy with directed biopsies and dilatation and curettage. A review of 276 cases. American journal of obstetrics and gynecology. 1988 Mar:158(3 Pt 1):489-92
[PubMed PMID: 3348309]
Level 2 (mid-level) evidence
[66]
Epstein E, Ramirez A, Skoog L, Valentin L. Dilatation and curettage fails to detect most focal lesions in the uterine cavity in women with postmenopausal bleeding. Acta obstetricia et gynecologica Scandinavica. 2001 Dec:80(12):1131-6
[PubMed PMID: 11846711]
[67]
Epstein E, Blomqvist L. Imaging in endometrial cancer. Best practice & research. Clinical obstetrics & gynaecology. 2014 Jul:28(5):721-39. doi: 10.1016/j.bpobgyn.2014.04.007. Epub 2014 Apr 30
[PubMed PMID: 24852891]
[68]
Simel DL, Matchar DB, Piscitelli JT. Routine intravenous pyelograms before hysterectomy in cases of benign disease: possibly effective, definitely expensive. American journal of obstetrics and gynecology. 1988 Nov:159(5):1049-53
[PubMed PMID: 3142261]
Level 3 (low-level) evidence
[69]
Piscitelli JT, Simel DL, Addison WA. Who should have intravenous pyelograms before hysterectomy for benign disease? Obstetrics and gynecology. 1987 Apr:69(4):541-5
[PubMed PMID: 3822294]
[70]
Barrow E, Robinson L, Alduaij W, Shenton A, Clancy T, Lalloo F, Hill J, Evans DG. Cumulative lifetime incidence of extracolonic cancers in Lynch syndrome: a report of 121 families with proven mutations. Clinical genetics. 2009 Feb:75(2):141-9. doi: 10.1111/j.1399-0004.2008.01125.x. Epub
[PubMed PMID: 19215248]
[71]
Hiatt MJ, Casey MJ, Lynch HT, Snyder CL, Stacey M, Walters RW. Efficacy of proximal colectomy for surgical management of right-sided first colorectal cancer in Lynch Syndrome mutation carriers. American journal of surgery. 2018 Jul:216(1):99-105. doi: 10.1016/j.amjsurg.2017.11.003. Epub 2017 Nov 8
[PubMed PMID: 29153248]
Level 3 (low-level) evidence
[72]
Secord AA, Hasselblad V, Von Gruenigen VE, Gehrig PA, Modesitt SC, Bae-Jump V, Havrilesky LJ. Body mass index and mortality in endometrial cancer: A systematic review and meta-analysis. Gynecologic oncology. 2016 Jan:140(1):184-90. doi: 10.1016/j.ygyno.2015.10.020. Epub 2015 Oct 31
[PubMed PMID: 26524722]
Level 1 (high-level) evidence
[73]
Gierisch JM, Coeytaux RR, Urrutia RP, Havrilesky LJ, Moorman PG, Lowery WJ, Dinan M, McBroom AJ, Hasselblad V, Sanders GD, Myers ER. Oral contraceptive use and risk of breast, cervical, colorectal, and endometrial cancers: a systematic review. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2013 Nov:22(11):1931-43. doi: 10.1158/1055-9965.EPI-13-0298. Epub 2013 Sep 6
[PubMed PMID: 24014598]
Level 1 (high-level) evidence
[74]
Soini T, Hurskainen R, Grénman S, Mäenpää J, Paavonen J, Pukkala E. Cancer risk in women using the levonorgestrel-releasing intrauterine system in Finland. Obstetrics and gynecology. 2014 Aug:124(2 Pt 1):292-299. doi: 10.1097/AOG.0000000000000356. Epub
[PubMed PMID: 25004338]
[75]
Brinton LA, Felix AS. Menopausal hormone therapy and risk of endometrial cancer. The Journal of steroid biochemistry and molecular biology. 2014 Jul:142():83-9. doi: 10.1016/j.jsbmb.2013.05.001. Epub 2013 May 13
[PubMed PMID: 23680641]
[76]
Gadducci A, Biglia N, Sismondi P, Genazzani AR. Breast cancer and sex steroids: critical review of epidemiological, experimental and clinical investigations on etiopathogenesis, chemoprevention and endocrine treatment of breast cancer. Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology. 2005 Jun:20(6):343-60
[PubMed PMID: 16019385]
Level 2 (mid-level) evidence
[77]
Johnatty SE, Tan YY, Buchanan DD, Bowman M, Walters RJ, Obermair A, Quinn MA, Blomfield PB, Brand A, Leung Y, Oehler MK, ANECS Group, Kirk JA, O'Mara TA, Webb PM, Spurdle AB. Family history of cancer predicts endometrial cancer risk independently of Lynch Syndrome: Implications for genetic counselling. Gynecologic oncology. 2017 Nov:147(2):381-387. doi: 10.1016/j.ygyno.2017.08.011. Epub 2017 Aug 17
[PubMed PMID: 28822557]
[78]
Schmeler KM, Lynch HT, Chen LM, Munsell MF, Soliman PT, Clark MB, Daniels MS, White KG, Boyd-Rogers SG, Conrad PG, Yang KY, Rubin MM, Sun CC, Slomovitz BM, Gershenson DM, Lu KH. Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. The New England journal of medicine. 2006 Jan 19:354(3):261-9
[PubMed PMID: 16421367]
[79]
Setiawan VW, Matsuno RK, Lurie G, Wilkens LR, Carney ME, Henderson BE, Kolonel LN, Goodman MT. Use of nonsteroidal anti-inflammatory drugs and risk of ovarian and endometrial cancer: the Multiethnic Cohort. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2012 Sep:21(9):1441-9. doi: 10.1158/1055-9965.EPI-12-0390-T. Epub 2012 Jun 4
[PubMed PMID: 22665579]
[80]
Verdoodt F, Kjaer SK, Friis S. Influence of aspirin and non-aspirin NSAID use on ovarian and endometrial cancer: Summary of epidemiologic evidence of cancer risk and prognosis. Maturitas. 2017 Jun:100():1-7. doi: 10.1016/j.maturitas.2017.03.001. Epub 2017 Mar 7
[PubMed PMID: 28539172]
[81]
Takiuchi T, Blake EA, Matsuo K, Sood AK, Brasky TM. Aspirin use and endometrial cancer risk and survival. Gynecologic oncology. 2018 Jan:148(1):222-232. doi: 10.1016/j.ygyno.2017.10.026. Epub 2017 Nov 11
[PubMed PMID: 29132875]
[82]
Renkonen-Sinisalo L, Bützow R, Leminen A, Lehtovirta P, Mecklin JP, Järvinen HJ. Surveillance for endometrial cancer in hereditary nonpolyposis colorectal cancer syndrome. International journal of cancer. 2007 Feb 15:120(4):821-4
[PubMed PMID: 17096354]
[83]
Gerritzen LH, Hoogerbrugge N, Oei AL, Nagengast FM, van Ham MA, Massuger LF, de Hullu JA. Improvement of endometrial biopsy over transvaginal ultrasound alone for endometrial surveillance in women with Lynch syndrome. Familial cancer. 2009:8(4):391-7. doi: 10.1007/s10689-009-9252-x. Epub 2009 Jun 6
[PubMed PMID: 19504173]
[84]
Malur S, Possover M, Michels W, Schneider A. Laparoscopic-assisted vaginal versus abdominal surgery in patients with endometrial cancer--a prospective randomized trial. Gynecologic oncology. 2001 Feb:80(2):239-44
[PubMed PMID: 11161866]
Level 1 (high-level) evidence
[85]
Magrina JF, Mutone NF, Weaver AL, Magtibay PM, Fowler RS, Cornella JL. Laparoscopic lymphadenectomy and vaginal or laparoscopic hysterectomy with bilateral salpingo-oophorectomy for endometrial cancer: morbidity and survival. American journal of obstetrics and gynecology. 1999 Aug:181(2):376-81
[PubMed PMID: 10454686]
[86]
Bell MC, Torgerson J, Seshadri-Kreaden U, Suttle AW, Hunt S. Comparison of outcomes and cost for endometrial cancer staging via traditional laparotomy, standard laparoscopy and robotic techniques. Gynecologic oncology. 2008 Dec:111(3):407-11. doi: 10.1016/j.ygyno.2008.08.022. Epub 2008 Oct 1
[PubMed PMID: 18829091]
[87]
Malzoni M, Tinelli R, Cosentino F, Perone C, Rasile M, Iuzzolino D, Malzoni C, Reich H. Total laparoscopic hysterectomy versus abdominal hysterectomy with lymphadenectomy for early-stage endometrial cancer: a prospective randomized study. Gynecologic oncology. 2009 Jan:112(1):126-33. doi: 10.1016/j.ygyno.2008.08.019. Epub 2008 Oct 22
[PubMed PMID: 18947861]
Level 1 (high-level) evidence
[88]
Boggess JF, Gehrig PA, Cantrell L, Shafer A, Ridgway M, Skinner EN, Fowler WC. A comparative study of 3 surgical methods for hysterectomy with staging for endometrial cancer: robotic assistance, laparoscopy, laparotomy. American journal of obstetrics and gynecology. 2008 Oct:199(4):360.e1-9. doi: 10.1016/j.ajog.2008.08.012. Epub
[PubMed PMID: 18928974]
Level 2 (mid-level) evidence
[89]
SGO Clinical Practice Endometrial Cancer Working Group, Burke WM, Orr J, Leitao M, Salom E, Gehrig P, Olawaiye AB, Brewer M, Boruta D, Villella J, Herzog T, Abu Shahin F, Society of Gynecologic Oncology Clinical Practice Committee. Endometrial cancer: a review and current management strategies: part I. Gynecologic oncology. 2014 Aug:134(2):385-92. doi: 10.1016/j.ygyno.2014.05.018. Epub 2014 Jun 4
[PubMed PMID: 24905773]
[90]
Corrado G, Cutillo G, Pomati G, Mancini E, Sperduti I, Patrizi L, Saltari M, Vincenzoni C, Baiocco E, Vizza E. Surgical and oncological outcome of robotic surgery compared to laparoscopic and abdominal surgery in the management of endometrial cancer. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology. 2015 Aug:41(8):1074-81. doi: 10.1016/j.ejso.2015.04.020. Epub 2015 May 9
[PubMed PMID: 26002986]
[91]
Mavromatis ID, Antonopoulos CN, Matsoukis IL, Frangos CC, Skalkidou A, Creatsas G, Petridou ET. Validity of intraoperative gross examination of myometrial invasion in patients with endometrial cancer: a meta-analysis. Acta obstetricia et gynecologica Scandinavica. 2012 Jul:91(7):779-93. doi: 10.1111/j.1600-0412.2012.01406.x. Epub 2012 Apr 30
[PubMed PMID: 22452291]
Level 1 (high-level) evidence
[92]
Kumar S, Medeiros F, Dowdy SC, Keeney GL, Bakkum-Gamez JN, Podratz KC, Cliby WA, Mariani A. A prospective assessment of the reliability of frozen section to direct intraoperative decision making in endometrial cancer. Gynecologic oncology. 2012 Dec:127(3):525-31. doi: 10.1016/j.ygyno.2012.08.024. Epub 2012 Aug 29
[PubMed PMID: 22940491]
[93]
Creasman WT, Morrow CP, Bundy BN, Homesley HD, Graham JE, Heller PB. Surgical pathologic spread patterns of endometrial cancer. A Gynecologic Oncology Group Study. Cancer. 1987 Oct 15:60(8 Suppl):2035-41
[PubMed PMID: 3652025]
[94]
Morrow CP, Bundy BN, Kurman RJ, Creasman WT, Heller P, Homesley HD, Graham JE. Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecologic oncology. 1991 Jan:40(1):55-65
[PubMed PMID: 1989916]
[95]
Mitamura T, Watari H, Todo Y, Kato T, Konno Y, Hosaka M, Sakuragi N. Lymphadenectomy can be omitted for low-risk endometrial cancer based on preoperative assessments. Journal of gynecologic oncology. 2014 Oct:25(4):301-5. doi: 10.3802/jgo.2014.25.4.301. Epub 2014 Jun 18
[PubMed PMID: 25142623]
[96]
Todo Y, Kato H, Kaneuchi M, Watari H, Takeda M, Sakuragi N. Survival effect of para-aortic lymphadenectomy in endometrial cancer (SEPAL study): a retrospective cohort analysis. Lancet (London, England). 2010 Apr 3:375(9721):1165-72. doi: 10.1016/S0140-6736(09)62002-X. Epub 2010 Feb 24
[PubMed PMID: 20188410]
Level 2 (mid-level) evidence
[97]
Todo Y, Okamoto K, Takeshita S, Sudo S, Kato H. A patient group at negligible risk of para-aortic lymph node metastasis in endometrial cancer. Gynecologic oncology. 2016 Apr:141(1):155-9. doi: 10.1016/j.ygyno.2016.01.024. Epub 2016 Jan 26
[PubMed PMID: 26825615]
[98]
Todo Y, Takeshita S, Okamoto K, Yamashiro K, Kato H. Implications of para-aortic lymph node metastasis in patients with endometrial cancer without pelvic lymph node metastasis. Journal of gynecologic oncology. 2017 Sep:28(5):e59. doi: 10.3802/jgo.2017.28.e59. Epub 2017 May 22
[PubMed PMID: 28657221]
[99]
Larson DM, Johnson KK. Pelvic and para-aortic lymphadenectomy for surgical staging of high-risk endometrioid adenocarcinoma of the endometrium. Gynecologic oncology. 1993 Dec:51(3):345-8
[PubMed PMID: 8112643]
[100]
Cragun JM, Havrilesky LJ, Calingaert B, Synan I, Secord AA, Soper JT, Clarke-Pearson DL, Berchuck A. Retrospective analysis of selective lymphadenectomy in apparent early-stage endometrial cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005 Jun 1:23(16):3668-75
[PubMed PMID: 15738538]
Level 2 (mid-level) evidence
[101]
Lutman CV, Havrilesky LJ, Cragun JM, Secord AA, Calingaert B, Berchuck A, Clarke-Pearson DL, Soper JT. Pelvic lymph node count is an important prognostic variable for FIGO stage I and II endometrial carcinoma with high-risk histology. Gynecologic oncology. 2006 Jul:102(1):92-7
[PubMed PMID: 16406063]
[102]
Chan JK, Cheung MK, Huh WK, Osann K, Husain A, Teng NN, Kapp DS. Therapeutic role of lymph node resection in endometrioid corpus cancer: a study of 12,333 patients. Cancer. 2006 Oct 15:107(8):1823-30
[PubMed PMID: 16977653]
[103]
Mariani A, Dowdy SC, Cliby WA, Gostout BS, Jones MB, Wilson TO, Podratz KC. Prospective assessment of lymphatic dissemination in endometrial cancer: a paradigm shift in surgical staging. Gynecologic oncology. 2008 Apr:109(1):11-8. doi: 10.1016/j.ygyno.2008.01.023. Epub 2008 Mar 4
[PubMed PMID: 18304622]
[104]
Abu-Rustum NR, Chi DS, Leitao M, Oke EA, Hensley ML, Alektiar KM, Barakat RR. What is the incidence of isolated paraaortic nodal recurrence in grade 1 endometrial carcinoma? Gynecologic oncology. 2008 Oct:111(1):46-8. doi: 10.1016/j.ygyno.2008.06.010. Epub 2008 Jul 26
[PubMed PMID: 18657853]
[105]
Kumar S, Mariani A, Bakkum-Gamez JN, Weaver AL, McGree ME, Keeney GL, Cliby WA, Podratz KC, Dowdy SC. Risk factors that mitigate the role of paraaortic lymphadenectomy in uterine endometrioid cancer. Gynecologic oncology. 2013 Sep:130(3):441-5. doi: 10.1016/j.ygyno.2013.05.035. Epub 2013 Jun 5
[PubMed PMID: 23747331]
[106]
Abu-Rustum NR, Gomez JD, Alektiar KM, Soslow RA, Hensley ML, Leitao MM Jr, Gardner GJ, Sonoda Y, Chi DS, Barakat RR. The incidence of isolated paraaortic nodal metastasis in surgically staged endometrial cancer patients with negative pelvic lymph nodes. Gynecologic oncology. 2009 Nov:115(2):236-8. doi: 10.1016/j.ygyno.2009.07.016. Epub 2009 Aug 9
[PubMed PMID: 19666190]
[107]
Kumar S, Podratz KC, Bakkum-Gamez JN, Dowdy SC, Weaver AL, McGree ME, Cliby WA, Keeney GL, Thomas G, Mariani A. Prospective assessment of the prevalence of pelvic, paraaortic and high paraaortic lymph node metastasis in endometrial cancer. Gynecologic oncology. 2014 Jan:132(1):38-43. doi: 10.1016/j.ygyno.2013.10.002. Epub 2013 Oct 9
[PubMed PMID: 24120926]
[108]
Sari ME, Yalcin İ, Sahin H, Meydanli MM, Gungor T. Risk factors for paraaortic lymph node metastasis in endometrial cancer. International journal of clinical oncology. 2017 Oct:22(5):937-944. doi: 10.1007/s10147-017-1139-5. Epub 2017 May 18
[PubMed PMID: 28523533]
[109]
Benedetti Panici P, Basile S, Maneschi F, Alberto Lissoni A, Signorelli M, Scambia G, Angioli R, Tateo S, Mangili G, Katsaros D, Garozzo G, Campagnutta E, Donadello N, Greggi S, Melpignano M, Raspagliesi F, Ragni N, Cormio G, Grassi R, Franchi M, Giannarelli D, Fossati R, Torri V, Amoroso M, Crocè C, Mangioni C. Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. Journal of the National Cancer Institute. 2008 Dec 3:100(23):1707-16. doi: 10.1093/jnci/djn397. Epub 2008 Nov 25
[PubMed PMID: 19033573]
Level 1 (high-level) evidence
[110]
ASTEC study group, Kitchener H, Swart AM, Qian Q, Amos C, Parmar MK. Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study. Lancet (London, England). 2009 Jan 10:373(9658):125-36. doi: 10.1016/S0140-6736(08)61766-3. Epub 2008 Dec 16
[PubMed PMID: 19070889]
Level 2 (mid-level) evidence
[111]
Watari H, Mitamura T, Moriwaki M, Hosaka M, Ohba Y, Sudo S, Todo Y, Takeda M, Ebina Y, Sakuragi N. Survival and failure pattern of patients with endometrial cancer after extensive surgery including systematic pelvic and para-aortic lymphadenectomy followed by adjuvant chemotherapy. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2009 Dec:19(9):1585-90. doi: 10.1111/IGC.0b013e3181a833cc. Epub
[PubMed PMID: 19955942]
Level 2 (mid-level) evidence
[112]
Khoury-Collado F, St Clair C, Abu-Rustum NR. Sentinel Lymph Node Mapping in Endometrial Cancer: An Update. The oncologist. 2016 Apr:21(4):461-6. doi: 10.1634/theoncologist.2015-0473. Epub 2016 Mar 9
[PubMed PMID: 26961924]
[113]
Joo WD, Schwartz PE, Rutherford TJ, Seong SJ, Ku J, Park H, Jung SG, Choi MC, Lee C. Microscopic Omental Metastasis in Clinical Stage I Endometrial Cancer: A Meta-analysis. Annals of surgical oncology. 2015 Oct:22(11):3695-700. doi: 10.1245/s10434-015-4443-1. Epub 2015 Feb 18
[PubMed PMID: 25691282]
Level 1 (high-level) evidence
[114]
Colombo N, Creutzberg C, Amant F, Bosse T, González-Martín A, Ledermann J, Marth C, Nout R, Querleu D, Mirza MR, Sessa C, ESMO-ESGO-ESTRO Endometrial Consensus Conference Working Group. ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up. Annals of oncology : official journal of the European Society for Medical Oncology. 2016 Jan:27(1):16-41. doi: 10.1093/annonc/mdv484. Epub 2015 Dec 2
[PubMed PMID: 26634381]
Level 3 (low-level) evidence
[115]
Matsuo K, Machida H, Stone RL, Soliman PT, Thaker PH, Roman LD, Wright JD. Risk of Subsequent Ovarian Cancer After Ovarian Conservation in Young Women With Stage I Endometrioid Endometrial Cancer. Obstetrics and gynecology. 2017 Aug:130(2):403-410. doi: 10.1097/AOG.0000000000002142. Epub
[PubMed PMID: 28697110]
[116]
Wright JD, Jorge S, Tergas AI, Hou JY, Burke WM, Huang Y, Hu JC, Ananth CV, Neugut AI, Hershman DL. Utilization and Outcomes of Ovarian Conservation in Premenopausal Women With Endometrial Cancer. Obstetrics and gynecology. 2016 Jan:127(1):101-108. doi: 10.1097/AOG.0000000000001181. Epub
[PubMed PMID: 26646128]
[117]
Gonthier C, Trefoux-Bourdet A, Koskas M. Impact of Conservative Managements in Young Women With Grade 2 or 3 Endometrial Adenocarcinoma Confined to the Endometrium. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2017 Mar:27(3):493-499. doi: 10.1097/IGC.0000000000000895. Epub
[PubMed PMID: 28187090]
Level 2 (mid-level) evidence
[118]
Matsuo K, Machida H, Shoupe D, Melamed A, Muderspach LI, Roman LD, Wright JD. Ovarian Conservation and Overall Survival in Young Women With Early-Stage Low-Grade Endometrial Cancer. Obstetrics and gynecology. 2016 Oct:128(4):761-70. doi: 10.1097/AOG.0000000000001647. Epub
[PubMed PMID: 27607873]
[119]
Shenfield CB, Pearcey RG, Ghosh S, Dundas GS. The management of inoperable Stage I endometrial cancer using intracavitary brachytherapy alone: a 20-year institutional review. Brachytherapy. 2009 Jul-Sep:8(3):278-83. doi: 10.1016/j.brachy.2008.11.006. Epub 2009 Feb 20
[PubMed PMID: 19230787]
[120]
Acharya S, Perkins SM, DeWees T, Fischer-Valuck BW, Mutch DG, Powell MA, Schwarz JK, Grigsby PW. Brachytherapy Is Associated With Improved Survival in Inoperable Stage I Endometrial Adenocarcinoma: A Population-Based Analysis. International journal of radiation oncology, biology, physics. 2015 Nov 1:93(3):649-57. doi: 10.1016/j.ijrobp.2015.06.013. Epub 2015 Jun 15
[PubMed PMID: 26461007]
[121]
Klopp A, Smith BD, Alektiar K, Cabrera A, Damato AL, Erickson B, Fleming G, Gaffney D, Greven K, Lu K, Miller D, Moore D, Petereit D, Schefter T, Small W Jr, Yashar C, Viswanathan AN. The role of postoperative radiation therapy for endometrial cancer: Executive summary of an American Society for Radiation Oncology evidence-based guideline. Practical radiation oncology. 2014 May-Jun:4(3):137-144. doi: 10.1016/j.prro.2014.01.003. Epub 2014 Mar 31
[PubMed PMID: 24766678]
Level 1 (high-level) evidence
[122]
Morice P, Leary A, Creutzberg C, Abu-Rustum N, Darai E. Endometrial cancer. Lancet (London, England). 2016 Mar 12:387(10023):1094-1108. doi: 10.1016/S0140-6736(15)00130-0. Epub 2015 Sep 6
[PubMed PMID: 26354523]
[123]
Kosary CL. FIGO stage, histology, histologic grade, age and race as prognostic factors in determining survival for cancers of the female gynecological system: an analysis of 1973-87 SEER cases of cancers of the endometrium, cervix, ovary, vulva, and vagina. Seminars in surgical oncology. 1994 Jan-Feb:10(1):31-46
[PubMed PMID: 8115784]
Level 2 (mid-level) evidence
[124]
Lee MH, Aquino-Parsons C, Hoskins PJ, Lim P, Kwon JS. Preoperative radiotherapy for inoperable stage II endometrial cancer: insights into improving treatment and outcomes. Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC. 2013 Jul:35(7):635-639. doi: 10.1016/S1701-2163(15)30893-8. Epub
[PubMed PMID: 23876641]
[125]
Ozgul N, Boyraz G, Salman MC, Gultekin M, Yuce K, Ibrahimov A, Erturk A, Gungorduk K, Gulseren V, Sanci M, Turkmen O, Karalok A, Kimyon G, Turan T, Ozkan NT, Meydanli MM, Gungor T, Ayik H, Simsek T. Oncological Outcomes of Stage II Endometrial Cancer: A Retrospective Analysis of 250 Cases. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2018 Jan:28(1):161-167. doi: 10.1097/IGC.0000000000001133. Epub
[PubMed PMID: 28930810]
Level 2 (mid-level) evidence
[126]
Cornelison TL, Trimble EL, Kosary CL. SEER data, corpus uteri cancer: treatment trends versus survival for FIGO stage II, 1988-1994. Gynecologic oncology. 1999 Sep:74(3):350-5
[PubMed PMID: 10479492]
[127]
Sartori E, Gadducci A, Landoni F, Lissoni A, Maggino T, Zola P, Zanagnolo V. Clinical behavior of 203 stage II endometrial cancer cases: the impact of primary surgical approach and of adjuvant radiation therapy. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2001 Nov-Dec:11(6):430-7
[PubMed PMID: 11906545]
Level 2 (mid-level) evidence
[128]
Cohn DE, Woeste EM, Cacchio S, Zanagnolo VL, Havrilesky LJ, Mariani A, Podratz KC, Huh WK, Whitworth JM, McMeekin DS, Powell MA, Boyd E, Phillips GS, Fowler JM. Clinical and pathologic correlates in surgical stage II endometrial carcinoma. Obstetrics and gynecology. 2007 May:109(5):1062-7
[PubMed PMID: 17470583]
[129]
Wright JD, Fiorelli J, Kansler AL, Burke WM, Schiff PB, Cohen CJ, Herzog TJ. Optimizing the management of stage II endometrial cancer: the role of radical hysterectomy and radiation. American journal of obstetrics and gynecology. 2009 Apr:200(4):419.e1-7. doi: 10.1016/j.ajog.2008.11.003. Epub 2009 Jan 10
[PubMed PMID: 19136095]
[130]
Gottschalk E, Lanowska M, Chiantera V, Marnitz S, Schneider A, Brink-Spalink V, Hasenbein K, Koehler C. Vaginal-assisted laparoscopic radical hysterectomy: rationale, technique, results. JSLS : Journal of the Society of Laparoendoscopic Surgeons. 2011 Oct-Dec:15(4):451-9. doi: 10.4293/108680811X13176785203879. Epub
[PubMed PMID: 22643498]
[131]
Vizza E, Chiofalo B, Cutillo G, Mancini E, Baiocco E, Zampa A, Bufalo A, Corrado G. Robotic single site radical hysterectomy plus pelvic lymphadenectomy in gynecological cancers. Journal of gynecologic oncology. 2018 Jan:29(1):e2. doi: 10.3802/jgo.2018.29.e2. Epub
[PubMed PMID: 29185260]
Level 2 (mid-level) evidence
[132]
Vargo JA, Boisen MM, Comerci JT, Kim H, Houser CJ, Sukumvanich P, Olawaiye AB, Kelley JL, Edwards RP, Huang M, Courtney-Brooks M, Beriwal S. Neoadjuvant radiotherapy with or without chemotherapy followed by extrafascial hysterectomy for locally advanced endometrial cancer clinically extending to the cervix or parametria. Gynecologic oncology. 2014 Nov:135(2):190-5. doi: 10.1016/j.ygyno.2014.09.001. Epub 2014 Sep 9
[PubMed PMID: 25218303]
[133]
Boisen MM, Vargo JA, Beriwal S, Sukumvanich P, Olawaiye AB, Kelley JL, Edwards RP, Huang M, Courtney-Brooks M, Comerci JT. Surgical Outcomes of Patients Undergoing Extrafascial Hysterectomy After Neoadjuvant Radiotherapy With or Without Chemotherapy for Locally Advanced Endometrial Cancer Clinically Extending to the Cervix or Parametria. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2017 Jul:27(6):1149-1154. doi: 10.1097/IGC.0000000000000614. Epub
[PubMed PMID: 26825835]
Level 2 (mid-level) evidence
[134]
Fishman DA, Roberts KB, Chambers JT, Kohorn EI, Schwartz PE, Chambers SK. Radiation therapy as exclusive treatment for medically inoperable patients with stage I and II endometrioid carcinoma with endometrium. Gynecologic oncology. 1996 May:61(2):189-96
[PubMed PMID: 8626131]
[135]
Dutta SW, Trifiletti DM, Grover S, Boimel P, Showalter TN. Management of elderly patients with early-stage medically inoperable endometrial cancer: Systematic review and National Cancer Database analysis. Brachytherapy. 2017 May-Jun:16(3):526-533. doi: 10.1016/j.brachy.2017.01.011. Epub 2017 Mar 3
[PubMed PMID: 28262518]
Level 1 (high-level) evidence
[136]
Goff BA, Goodman A, Muntz HG, Fuller AF Jr, Nikrui N, Rice LW. Surgical stage IV endometrial carcinoma: a study of 47 cases. Gynecologic oncology. 1994 Feb:52(2):237-40
[PubMed PMID: 8314145]
Level 3 (low-level) evidence
[137]
Bristow RE, Zerbe MJ, Rosenshein NB, Grumbine FC, Montz FJ. Stage IVB endometrial carcinoma: the role of cytoreductive surgery and determinants of survival. Gynecologic oncology. 2000 Aug:78(2):85-91
[PubMed PMID: 10926785]
[138]
Chi DS, Barakat RR. Surgical management of advanced or recurrent endometrial cancer. The Surgical clinics of North America. 2001 Aug:81(4):885-96
[PubMed PMID: 11551132]
[139]
Bristow RE, Zahurak ML, Alexander CJ, Zellars RC, Montz FJ. FIGO stage IIIC endometrial carcinoma: resection of macroscopic nodal disease and other determinants of survival. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2003 Sep-Oct:13(5):664-72
[PubMed PMID: 14675352]
Level 2 (mid-level) evidence
[140]
Lambrou NC, Gómez-Marín O, Mirhashemi R, Beach H, Salom E, Almeida-Parra Z, Peñalver M. Optimal surgical cytoreduction in patients with Stage III and Stage IV endometrial carcinoma: a study of morbidity and survival. Gynecologic oncology. 2004 Jun:93(3):653-8
[PubMed PMID: 15196860]
[141]
Awtrey CS, Cadungog MG, Leitao MM, Alektiar KM, Aghajanian C, Hummer AJ, Barakat RR, Chi DS. Surgical resection of recurrent endometrial carcinoma. Gynecologic oncology. 2006 Sep:102(3):480-8
[PubMed PMID: 16490236]
[142]
Bristow RE, Santillan A, Zahurak ML, Gardner GJ, Giuntoli RL 2nd, Armstrong DK. Salvage cytoreductive surgery for recurrent endometrial cancer. Gynecologic oncology. 2006 Oct:103(1):281-7
[PubMed PMID: 16631236]
[143]
Shih KK, Yun E, Gardner GJ, Barakat RR, Chi DS, Leitao MM Jr. Surgical cytoreduction in stage IV endometrioid endometrial carcinoma. Gynecologic oncology. 2011 Sep:122(3):608-11. doi: 10.1016/j.ygyno.2011.05.020. Epub 2011 Jun 12
[PubMed PMID: 21664663]
[144]
Papadia A, Bellati F, Ditto A, Bogani G, Gasparri ML, Di Donato V, Martinelli F, Lorusso D, Benedetti-Panici P, Raspagliesi F. Surgical Treatment of Recurrent Endometrial Cancer: Time for a Paradigm Shift. Annals of surgical oncology. 2015 Dec:22(13):4204-10. doi: 10.1245/s10434-015-4504-5. Epub 2015 Mar 17
[PubMed PMID: 25777095]
[145]
Barlin JN, Puri I, Bristow RE. Cytoreductive surgery for advanced or recurrent endometrial cancer: a meta-analysis. Gynecologic oncology. 2010 Jul:118(1):14-8. doi: 10.1016/j.ygyno.2010.04.005. Epub
[PubMed PMID: 20434198]
Level 1 (high-level) evidence
[146]
Vandenput I, Van Calster B, Capoen A, Leunen K, Berteloot P, Neven P, Moerman P, Vergote I, Amant F. Neoadjuvant chemotherapy followed by interval debulking surgery in patients with serous endometrial cancer with transperitoneal spread (stage IV): a new preferred treatment? British journal of cancer. 2009 Jul 21:101(2):244-9. doi: 10.1038/sj.bjc.6605157. Epub 2009 Jun 30
[PubMed PMID: 19568245]
[147]
Dabi Y, Uzan J, Bendifallah S, Ouldamer L, Lavoué V, Canlorbe G, Raimond E, Coutant C, Graesslin O, Collinet P, Bricou A, Daraï E, Ballester M, Haddad B, Touboul C, Groupe de Recherche FRANCOGYN. Prognostic value of local relapse for patients with endometrial cancer. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology. 2017 Nov:43(11):2143-2149. doi: 10.1016/j.ejso.2017.08.004. Epub 2017 Aug 31
[PubMed PMID: 28870426]
[148]
Kamrava M, Beriwal S, Erickson B, Gaffney D, Jhingran A, Klopp A, Park SJ, Viswanathan A, Yashar C, Lin L. American Brachytherapy Society recurrent carcinoma of the endometrium task force patterns of care and review of the literature. Brachytherapy. 2017 Nov-Dec:16(6):1129-1143. doi: 10.1016/j.brachy.2017.07.012. Epub 2017 Sep 6
[PubMed PMID: 28888417]
[149]
Barakat RR, Goldman NA, Patel DA, Venkatraman ES, Curtin JP. Pelvic exenteration for recurrent endometrial cancer. Gynecologic oncology. 1999 Oct:75(1):99-102
[PubMed PMID: 10502433]
[150]
Colombo N, Creutzberg C, Amant F, Bosse T, González-Martín A, Ledermann J, Marth C, Nout R, Querleu D, Mirza MR, Sessa C, ESMO-ESGO-ESTRO Endometrial Consensus Conference Working Group. ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: Diagnosis, Treatment and Follow-up. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2016 Jan:26(1):2-30. doi: 10.1097/IGC.0000000000000609. Epub
[PubMed PMID: 26645990]
Level 2 (mid-level) evidence
[151]
Creutzberg CL, van Putten WL, Koper PC, Lybeert ML, Jobsen JJ, Wárlám-Rodenhuis CC, De Winter KA, Lutgens LC, van den Bergh AC, van de Steen-Banasik E, Beerman H, van Lent M. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma. Lancet (London, England). 2000 Apr 22:355(9213):1404-11
[PubMed PMID: 10791524]
Level 1 (high-level) evidence
[152]
Scholten AN, van Putten WL, Beerman H, Smit VT, Koper PC, Lybeert ML, Jobsen JJ, Wárlám-Rodenhuis CC, De Winter KA, Lutgens LC, van Lent M, Creutzberg CL, PORTEC Study Group. Postoperative radiotherapy for Stage 1 endometrial carcinoma: long-term outcome of the randomized PORTEC trial with central pathology review. International journal of radiation oncology, biology, physics. 2005 Nov 1:63(3):834-8
[PubMed PMID: 15927414]
Level 1 (high-level) evidence
[153]
Kong A, Johnson N, Kitchener HC, Lawrie TA. Adjuvant radiotherapy for stage I endometrial cancer. The Cochrane database of systematic reviews. 2012 Mar 14:(3):CD003916. doi: 10.1002/14651858.CD003916.pub3. Epub 2012 Mar 14
[PubMed PMID: 22419290]
Level 1 (high-level) evidence
[154]
Morneau M, Foster W, Lalancette M, Van Nguyen-Huynh T, Renaud MC, Samouëlian V, Letarte N, Comité de l'évolution des pratiques en oncologie, Comité de l'évolution des pratiques en oncologie, Almanric K, Boily G, Bouchard P, Boulanger J, Cournoyer G, Couture F, Gervais N, Goulet S, Guay MP, Kavanagh M, Lemieux J, Lespérance B, Letarte N, Morneau M, Ouellet JF, Pineau G, Rajan R, Roy I, Samson B, Sidéris L, Vincent F. Adjuvant treatment for endometrial cancer: literature review and recommendations by the Comité de l'évolution des pratiques en oncologie (CEPO). Gynecologic oncology. 2013 Oct:131(1):231-40. doi: 10.1016/j.ygyno.2013.07.084. Epub 2013 Jul 19
[PubMed PMID: 23872191]
[155]
SGO Clinical Practice Endometrial Cancer Working Group, Burke WM, Orr J, Leitao M, Salom E, Gehrig P, Olawaiye AB, Brewer M, Boruta D, Herzog TJ, Shahin FA, Society of Gynecologic Oncology Clinical Practice Committee. Endometrial cancer: a review and current management strategies: part II. Gynecologic oncology. 2014 Aug:134(2):393-402. doi: 10.1016/j.ygyno.2014.06.003. Epub 2014 Jun 11
[PubMed PMID: 24929052]
[156]
Harkenrider MM, Block AM, Siddiqui ZA, Small W Jr. The role of vaginal cuff brachytherapy in endometrial cancer. Gynecologic oncology. 2015 Feb:136(2):365-72. doi: 10.1016/j.ygyno.2014.12.036. Epub 2014 Dec 31
[PubMed PMID: 25555710]
[157]
Paydar I, DeWees T, Powell M, Mutch DG, Grigsby PW, Schwarz JK. Adjuvant radiotherapy in Stage II endometrial carcinoma: Is brachytherapy alone sufficient for local control? Brachytherapy. 2015 Jul-Aug:14(4):427-32. doi: 10.1016/j.brachy.2015.02.196. Epub 2015 Apr 22
[PubMed PMID: 25911995]
[158]
Chen KS, Berhane H, Gill BS, Olawaiye A, Sukumvanich P, Kelley JL, Boisen MM, Courtney-Brooks M, Comerci JT, Edwards R, Berger J, Beriwal S. Outcomes of stage II endometrial cancer: The UPMC Hillman Cancer Center experience. Gynecologic oncology. 2017 Nov:147(2):315-319. doi: 10.1016/j.ygyno.2017.08.021. Epub 2017 Aug 31
[PubMed PMID: 28866431]
[159]
Lester-Coll NH, Young MR, Park HS, Ratner ES, Litkouhi B, Damast S. Adjuvant Therapy Use and Survival in Stage II Endometrial Cancer. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2017 Nov:27(9):1904-1911. doi: 10.1097/IGC.0000000000001095. Epub
[PubMed PMID: 28763364]
Level 2 (mid-level) evidence
[160]
Rossi PJ, Jani AB, Horowitz IR, Johnstone PA. Adjuvant brachytherapy removes survival disadvantage of local disease extension in stage IIIC endometrial cancer: a SEER registry analysis. International journal of radiation oncology, biology, physics. 2008 Jan 1:70(1):134-8
[PubMed PMID: 17855014]
[161]
Huddleston A, Zhen S, Qi L, Rash D, Leiserowitz G, Mayadev J. The impact of a vaginal brachytherapy boost to pelvic radiation in stage III endometrial cancer. Journal of contemporary brachytherapy. 2015 Apr:7(2):122-7. doi: 10.5114/jcb.2015.50877. Epub 2015 Apr 20
[PubMed PMID: 26034492]
Level 2 (mid-level) evidence
[162]
Lester-Coll NH, Park HS, Rutter CE, Corso CD, Young MR, Ratner ES, Litkouhi B, Decker RH, Yu JB, Damast S. Who benefits from chemoradiation in stage III-IVA endometrial cancer? An analysis of the National Cancer Data Base. Gynecologic oncology. 2016 Jul:142(1):54-61. doi: 10.1016/j.ygyno.2016.04.544. Epub 2016 May 13
[PubMed PMID: 27151429]
[163]
Shaikh T, Churilla TM, Mantia-Smaldone GM, Chu C, Rubin SC, Anderson PR. The role of adjuvant radiation in lymph node positive endometrial adenocarcinoma. Gynecologic oncology. 2016 Jun:141(3):434-439. doi: 10.1016/j.ygyno.2016.04.010. Epub 2016 Apr 21
[PubMed PMID: 27090796]
[164]
Bingham B, Orton A, Boothe D, Stoddard G, Huang YJ, Gaffney DK, Poppe MM. Brachytherapy Improves Survival in Stage III Endometrial Cancer With Cervical Involvement. International journal of radiation oncology, biology, physics. 2017 Apr 1:97(5):1040-1050. doi: 10.1016/j.ijrobp.2016.12.035. Epub 2017 Jan 4
[PubMed PMID: 28332987]
[165]
Holloway CL, Alexander C, Walter C, Aquino-Parsons C, Truong PT. Stage IIIC Endometrial Cancer: Relapse and Survival Outcomes in Women Treated With Pelvic or Extended Field Para-Aortic Nodal Radiation Therapy. American journal of clinical oncology. 2017 Oct:40(5):458-463. doi: 10.1097/COC.0000000000000192. Epub
[PubMed PMID: 25844822]
[166]
Schwandt A, Chen WC, Martra F, Zola P, Debernardo R, Kunos CA. Chemotherapy plus radiation in advanced-stage endometrial cancer. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2011 Dec:21(9):1622-7. doi: 10.1097/IGC.0b013e31822b6594. Epub
[PubMed PMID: 21897269]
Level 2 (mid-level) evidence
[167]
Kuku S, Williams M, McCormack M. Adjuvant therapy in stage III endometrial cancer: treatment outcomes and survival. a single-institution retrospective study. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2013 Jul:23(6):1056-64. doi: 10.1097/IGC.0b013e3182978328. Epub
[PubMed PMID: 23765205]
Level 2 (mid-level) evidence
[168]
Signorelli M, Lissoni AA, De Ponti E, Grassi T, Ponti S, Fruscio R. Adjuvant sequential chemo and radiotherapy improves the oncological outcome in high risk endometrial cancer. Journal of gynecologic oncology. 2015 Oct:26(4):284-92. doi: 10.3802/jgo.2015.26.4.284. Epub 2015 Jul 14
[PubMed PMID: 26197768]
[169]
Boothe D, Orton A, Odei B, Stoddard G, Suneja G, Poppe MM, Werner TL, Gaffney DK. Chemoradiation versus chemotherapy or radiation alone in stage III endometrial cancer: Patterns of care and impact on overall survival. Gynecologic oncology. 2016 Jun:141(3):421-427. doi: 10.1016/j.ygyno.2016.03.021. Epub 2016 Apr 2
[PubMed PMID: 27005441]
[170]
Bestvina CM, Fleming GF. Chemotherapy for Endometrial Cancer in Adjuvant and Advanced Disease Settings. The oncologist. 2016 Oct:21(10):1250-1259
[PubMed PMID: 27412393]
[171]
Bregar A, Robison K, Dizon DS. Update on the chemotherapeutic management of endometrial cancer. Clinical advances in hematology & oncology : H&O. 2014 Oct:12(10):659-65
[PubMed PMID: 25658891]
Level 3 (low-level) evidence
[172]
Ledermann JA. PARP inhibitors in ovarian cancer. Annals of oncology : official journal of the European Society for Medical Oncology. 2016 Apr:27 Suppl 1():i40-i44. doi: 10.1093/annonc/mdw094. Epub
[PubMed PMID: 27141070]
[173]
Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D, Biedrzycki B, Donehower RC, Zaheer A, Fisher GA, Crocenzi TS, Lee JJ, Duffy SM, Goldberg RM, de la Chapelle A, Koshiji M, Bhaijee F, Huebner T, Hruban RH, Wood LD, Cuka N, Pardoll DM, Papadopoulos N, Kinzler KW, Zhou S, Cornish TC, Taube JM, Anders RA, Eshleman JR, Vogelstein B, Diaz LA Jr. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. The New England journal of medicine. 2015 Jun 25:372(26):2509-20. doi: 10.1056/NEJMoa1500596. Epub 2015 May 30
[PubMed PMID: 26028255]
[174]
Howitt BE, Shukla SA, Sholl LM, Ritterhouse LL, Watkins JC, Rodig S, Stover E, Strickland KC, D'Andrea AD, Wu CJ, Matulonis UA, Konstantinopoulos PA. Association of Polymerase e-Mutated and Microsatellite-Instable Endometrial Cancers With Neoantigen Load, Number of Tumor-Infiltrating Lymphocytes, and Expression of PD-1 and PD-L1. JAMA oncology. 2015 Dec:1(9):1319-23. doi: 10.1001/jamaoncol.2015.2151. Epub
[PubMed PMID: 26181000]
[175]
Pecorelli S. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics. 2009 May:105(2):103-4
[PubMed PMID: 19367689]
[176]
Seagle BL, Alexander AL, Lantsman T, Shahabi S. Prognosis and treatment of positive peritoneal cytology in early endometrial cancer: matched cohort analyses from the National Cancer Database. American journal of obstetrics and gynecology. 2018 Mar:218(3):329.e1-329.e15. doi: 10.1016/j.ajog.2017.11.601. Epub 2017 Dec 6
[PubMed PMID: 29223598]
[177]
Greer BE, Koh WJ, Abu-Rustum N, Bookman MA, Bristow RE, Campos SM, Cho KR, Copeland L, Crispens MA, Eifel PJ, Huh WK, Jaggernauth W, Kapp DS, Kavanagh JJ, Lurain JR 3rd, Morgan M, Morgan RJ, Powell CB, Remmenga SW, Reynolds RK, Alvarez Secord A, Small W Jr, Teng N. Uterine Neoplasms. Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network : JNCCN. 2009 May:7(5):498-531
[PubMed PMID: 19460278]
Level 1 (high-level) evidence
[178]
Salani R, Backes FJ, Fung MF, Holschneider CH, Parker LP, Bristow RE, Goff BA. Posttreatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncologists recommendations. American journal of obstetrics and gynecology. 2011 Jun:204(6):466-78. doi: 10.1016/j.ajog.2011.03.008. Epub
[PubMed PMID: 21752752]
[179]
Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA: a cancer journal for clinicians. 2023 Jan:73(1):17-48. doi: 10.3322/caac.21763. Epub
[PubMed PMID: 36633525]
[180]
Clarke MA,Devesa SS,Hammer A,Wentzensen N, Racial and Ethnic Differences in Hysterectomy-Corrected Uterine Corpus Cancer Mortality by Stage and Histologic Subtype. JAMA oncology. 2022 Jun 1;
[PubMed PMID: 35511145]